UBS Group AG - RECRO PHARMA INC ownership

RECRO PHARMA INC's ticker is REPH and the CUSIP is 75629F109. A total of 48 filers reported holding RECRO PHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of RECRO PHARMA INC
ValueSharesWeighting
Q3 2023$3,823
-51.2%
8,151
+55.1%
0.00%
Q4 2022$7,828
-21.7%
5,254
-58.9%
0.00%
Q2 2022$10,000
-9.1%
12,785
+112.8%
0.00%
Q1 2022$11,000
+22.2%
6,007
+19.3%
0.00%
Q4 2021$9,000
-25.0%
5,034
-15.5%
0.00%
Q3 2021$12,000
-29.4%
5,956
-17.6%
0.00%
Q2 2021$17,000
+88.9%
7,227
+117.6%
0.00%
Q1 2021$9,000
+12.5%
3,321
+22.3%
0.00%
Q4 2020$8,000
-72.4%
2,715
-57.5%
0.00%
Q2 2020$29,000
-71.0%
6,390
-47.6%
0.00%
Q1 2020$100,000
-84.0%
12,197
-64.2%
0.00%
Q4 2019$624,000
+216.8%
34,073
+91.7%
0.00%
Q3 2019$197,000
+155.8%
17,777
+132.6%
0.00%
Q2 2019$77,000
+220.8%
7,642
+85.3%
0.00%
Q1 2019$24,000
-70.4%
4,125
-63.7%
0.00%
Q4 2018$81,000
+30.6%
11,354
+30.7%
0.00%
Q3 2018$62,000
+138.5%
8,690
+65.5%
0.00%
Q2 2018$26,000
+52.9%
5,251
+231.7%
0.00%
Q1 2018$17,000
+88.9%
1,583
+71.0%
0.00%
Q4 2017$9,000
+80.0%
926
+69.3%
0.00%
Q3 2017$5,000
+400.0%
547
+447.0%
0.00%
Q2 2017$1,000
-85.7%
100
-87.7%
0.00%
Q4 2016$7,000
-41.7%
812
-48.1%
0.00%
Q2 2016$12,000
-42.9%
1,565
-56.0%
0.00%
Q1 2016$21,000
+2000.0%
3,555
+3102.7%
0.00%
Q4 2015$1,000
-97.3%
111
-96.3%
0.00%
Q3 2015$37,000
+270.0%
3,038
+183.1%
0.00%
Q1 2015$10,000
-28.6%
1,073
-78.1%
0.00%
Q4 2014$14,0004,8940.00%
Other shareholders
RECRO PHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
Samjo Capital LLC 8,039,100$3,770,3381.48%
First Light Asset Management, LLC 19,676,396$9,228,2300.88%
AWM Investment Company, Inc. 10,266,144$4,814,8220.71%
Caligan Partners LP 1,689,768$794,1910.36%
HighMark Wealth Management LLC 484,985$227,4580.19%
Nantahala Capital Management 1,250,000$586,2500.05%
Clear Harbor Asset Management, LLC 938,847$440,3190.05%
DRIEHAUS CAPITAL MANAGEMENT LLC 4,249,229$1,992,8880.03%
TITLEIST ASSET MANAGEMENT, LLC 210,148$98,5590.02%
ROYCE & ASSOCIATES LP 3,285,082$1,540,7030.02%
View complete list of RECRO PHARMA INC shareholders